Diabetes

Teleretinal Screening: Closing the Gap in Diabetic Eye Care

Meeting patients where they are—community health centers—can improve screening rates and save vision.

Alice C. Lorch, MD, MPH

Advances in Therapy for Diabetic Eye Disease

The pipeline is rich with therapies that promise reduced treatment burden and improved efficacy.

Alicia H. Chen, MD; Jacob Holland, BS; and Sally S. Ong, MD

DR Stability With Automated Insulin Delivery

Our study indicates the benefits of improved glycemic control outweigh the small potential risk of worsening diabetic eye disease.

Francesc March de Ribot, MD, PhD, and Ben Wheeler, MD, PhD

PDR in the Setting of Oculocutaneous Albinism

Panretinal photocoagulation was sufficient to treat this patient’s vitreous hemorrhage and extensive neovascularization.

James Dossett, MD; Christine Clavell, MD; and Ghassan Ghorayeb, MD, MBA

Managing DR in Patients with Good Vision

The DRCR Retina Network sheds light on the optimal treatment approaches.

Gage Hazelton, BA, and Deepak Sambhara, MD

Utility of Fluorescein Angiography in DME

If you want to assess vessel leakage and peripheral pathology in diabetic eye disease, FA is still your best bet.

Jason Keil, MD, PhD; Caitlyn Cooper, MA; and Yannis M. Paulus, MD

The Emerging Role of AI in DR Screening

AI-powered technologies could help ophthalmologists meet the growing needs of this patient population.

Jorge C. P. Rocha, MD, PhD, and Majda Hadziahmetovic, MD

GLP-1 Receptor Agonists and the Eye

Researchers are working to understand the effects of these popular new therapies on ocular structures.

Suraj Bala, BS; Julia H. Joo, MD; and Aleksandra V. Rachitskaya, MD, FASRS

A Call for Holistic Care

Allen C. Ho, MD, and Robert L. Avery, MD

Minding the Gap: Diabetes Day Reduces Barriers to Care

Growing statewide effort increases access to diabetic eye care and reduces preventable blindness through free screening services.

Christian D. Raimondo, MS; Leah Prischak, BS; Charlotte N. Shields, MD; Rachel E. Cain; Elizabeth Goldstein, BS; Madison Woods, BS; Ari H. August, BA; Arslon Humayun, BA; and Allen C. Ho, MD

Modern Diabetes Care: What You Need to Know

The changing landscape of systemic diabetes care is affecting ocular complications such as diabetic retinopathy.

Samaantar Joshi, BS; Khiem Sy Nguyen, BS; Jonathan B. Lin, MD, PhD; and Ehsan Rahimy, MD

Teaching Fibrovascular Membrane Dissection

Use this structured approach to teach fellows how to manage complex diabetic eye disease in the OR.

James Rice, FCOphth(SA), MPH; Thabang Morris, FCOphth(SA); and Jonel Steffen, FCOphth(SA)

Limited Membranectomy for Diabetic TRD

This technique may be an effective option for select patients with diabetic tractional retinal detachment.

Taku Wakabayashi, MD, PhD, and Yusuke Oshima, MD, PhD

The Therapeutic Landscape for Diabetic Eye Disease

Many novel approaches are chugging through the pipeline, with promising data from phase 2 and 3 trials.

Yingna Snowy Liu, MD; Shane Griffin, MD, MCR; and Chirag D. Jhaveri, MD

Transvitreal Fibrinoid Reaction: A Rare Complication

Be prepared to handle this adverse event following vitrectomy in patients with diabetic retinopathy.

Yaqoob Qaseem, MD, and Jayanth Sridhar, MD

Complicated DR Cases: The Second Surgery

Taking patients with diabetes to the OR requires careful planning and expert execution, particularly when it’s a reoperation.

Adrian Au, MD, PhD; Blake Fortes, MD; and Pradeep Prasad, MD, MBA

Combination Therapy Considerations for DME

A summary of treatment options for patients who respond poorly to initial anti-VEGF treatment.

Justin Grad, MD(C); Amin Hatamnejad, MD; and Netan Choudhry, MD, FRCSC, FASRS, DABO

Managing DR in Pregnancy: A (Not-So) Hot Topic

Barriers to proper screening and care threaten the vision of this unique subset of patients with diabetes.

Swara Sarvepalli, MD, and Majda Hadziahmetovic, MD

Perseverance is Key

Allen C. Ho, MD, and Robert L. Avery, MD

Managing DME in the Age of Second-Generation Therapies

New treatment options raise questions regarding proper patient selection and dosing intervals. Here’s what we know so far.

Jack Lemon, MD, and Michael S. Ip, MD